Abstract | OBJECTIVES: METHODS: Twenty patients 4 to 17 years old received 0.8 mg of etanercept per kilogram of body weight subcutaneously once weekly for 3 months in an open multicentre trial. Active polyarticular disease was defined by the presence of five or more active joints with swelling, alternatively with pain or tenderness combined with limitation of motion. Safety assessments were based on adverse events (AEs) reports. Efficacy was assessed using the PedACR30/50/70 criteria. RESULTS: At the start of treatment the patients showed high disease activity. A rapid reduction of all disease activity parameters was observed. A PedACR30/50/70 response was reached by 75%/35%/10% of patients after 4 weeks, 90%/75%/35% after 8 weeks and 95%/75%/75% after 12 weeks of treatment. There were 37 AEs, none of them serious, with injection site reactions and minor infections being the most frequent. There was no drop out. Long-term follow-up of the patients will be carried out in the German JIA Registry. CONCLUSION:
|
Authors | Gerd Horneff, Annette Ebert, Sigrid Fitter, Kirsten Minden, Ivan Foeldvari, Jasmin Kümmerle-Deschner, Angelika Thon, Herrmann J Girschick, Frank Weller, Hans I Huppertz |
Journal | Rheumatology (Oxford, England)
(Rheumatology (Oxford))
Vol. 48
Issue 8
Pg. 916-9
(Aug 2009)
ISSN: 1462-0332 [Electronic] England |
PMID | 19483091
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Etanercept
|
Topics |
- Adolescent
- Antirheumatic Agents
(therapeutic use)
- Arthritis, Juvenile
(drug therapy)
- Child
- Child, Preschool
- Drug Administration Schedule
- Etanercept
- Female
- Humans
- Immunoglobulin G
(therapeutic use)
- Male
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Treatment Outcome
|